Ghent University Academic Bibliography

Mark

Network modeling of microRNA-mRNA interactions in neuroblastoma tumorigenesis identifies miR-204 as a direct inhibitor of MYCN

Chi Yan Ooi, Daniel R Carter, Bing Liu, Chelsea Mayoh, Anneleen Beckers, Amit Lalwani, Zsuzsanna Nagy, Sara De Brouwer, Bieke Decaesteker, Tzong-Tyng Hung, et al.

(2018) CANCER RESEARCH. 78(12). p.3122-3034

Mark

journalArticle
open access

A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk

Yingchang Lu, Alicia Beeghly-Fadiel, Lang Wu, Xingyi Guo, Bingshan Li, Joellen M. Schildkraut, Hae Kyung Im, Yian A. Chen, Jennifer B. Permuth, Brett M. Reid, et al.

(2018) Cancer Research. 78(18). p.5419-5430

Mark

A novel L-asparaginase with low L-glutaminase coactivity is highly efficacious against both T- and B-cell acute lymphoblastic leukemias in vivo

Hien Anh Nguyen, Ying Su, Jenny Yu Zhang, Aleksandar Antanasijevic, Michael Caffrey, Amanda M Schalk, Li Liu, Damiano Rondelli, Annie Oh, Dolores L Mahmud, et al.

(2018) CANCER RESEARCH. 78(6). p.1549-1560

Mark

Delivering type I interferon to dendritic cells empowers tumor eradication and immune combination treatments

Anje Cauwels (UGent) , Sandra Van Lint (UGent) , Franciane Paul, Genevieve Garcin, Stefaan De Koker (UGent) , Alexander Van Parys (UGent) , Thomas Wüest (UGent) , Sarah Gerlo (UGent) , José Van Der Heyden (UGent) , Yan Bordat, et al.

(2018) CANCER RESEARCH. 78(2). p.463-474

Mark

conference

Abstract 5027: Heterocellular 3D scaffolds as biomimetic to recapitulate the tumor microenvironment of peritoneal metastases in vitro and in vivo

Olivier De Wever (UGent) , Emiel De Jaeghere (UGent) and Elly De Vlieghere (UGent)

(2018) Cancer Research. 78(13 Supplement). p.5027-5027

Mark

BELIS : safety and tolerability of at home administration of trastuzumab (Herceptin (R)) subcutaneous for the treatment of patients with HER2-positive early breast cancer

Veronique Cocquyt (UGent) , CL Martinez-Mena, MT Martens, RG D'Hondt, M-PL Graas, E Evron, G Fried, NE Ben-Baruch, AC Dijkstra and EI Van De Walle

(2017) CANCER RESEARCH. 77(suppl. 4).

Mark

An accessible proteogenomics informatics resource for cancer researchers

Matthew C Chambers, Pratik D Jagtap, James E Johnson, Thomas McGowan, Praveen Kumar, Getiria Onsongo, Candace R Guerrero, Harald Barsnes, Marc Vaudel, Lennart Martens (UGent) , et al.

(2017) CANCER RESEARCH. 77(21). p.e43-e46

Mark

BRCA2 hypomorphic missense variants confer moderate risks of breast cancer

Hermela Shimelis, Romy LS Mesman, Catharina Von Nicolai, Asa Ehlen, Lucia Guidugli, Charlotte Martin, Fabienne MGR Calléja, Huong Meeks, Emily Hallberg, Jamie Hinton, et al.

(2017) CANCER RESEARCH. 77(11). p.2789-2799

Mark

Selective cross-cohort discovery of transcriptional mechanisms presiding over high-risk neuroblastoma subtype state maintenance

Presha Rajbhandari, Gonzalo Lopez, Jiyang Yu, Ruth Rodriguez-Barrueco, Mariano Alvarez, Daniel Martinez, Mark Yarmarkovich, Jo Vandesompele (UGent) , Pieter Mestdagh (UGent) , Jose M Silva, et al.

(2016) In CANCER RESEARCH 76(suppl. 14).

Mark

Eradication of neuroblastoma by suppressing the expression of a single long noncoding RNA

Pei Y Liu, Andrew E Tee, Bernard Atmadibrata, Pieter Mestdagh (UGent) , Jo Vandesompele (UGent) , Marcel Dinger and Tao Liu

(2016) In CANCER RESEARCH 76(suppl. 6).

Academic Bibliography

Network modeling of microRNA-mRNA interactions in neuroblastoma tumorigenesis identifies miR-204 as a direct inhibitor of MYCN

A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk

A novel L-asparaginase with low L-glutaminase coactivity is highly efficacious against both T- and B-cell acute lymphoblastic leukemias in vivo

Delivering type I interferon to dendritic cells empowers tumor eradication and immune combination treatments

Abstract 5027: Heterocellular 3D scaffolds as biomimetic to recapitulate the tumor microenvironment of peritoneal metastases in vitro and in vivo

BELIS : safety and tolerability of at home administration of trastuzumab (Herceptin (R)) subcutaneous for the treatment of patients with HER2-positive early breast cancer

An accessible proteogenomics informatics resource for cancer researchers

BRCA2 hypomorphic missense variants confer moderate risks of breast cancer

Selective cross-cohort discovery of transcriptional mechanisms presiding over high-risk neuroblastoma subtype state maintenance

Eradication of neuroblastoma by suppressing the expression of a single long noncoding RNA

Contents

Support

Contact